Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany

European Journal of Health Economics

Volumn 8, Issue 1, 2007, Pages 51-57

  Bruggenjurgen B ^a,b   Lindgren, P ^c   Ehlken, B ^d   Rupprecht, H J ^e   Willich, S N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Alpha Care Management and Research in Health Care Systems   (Germany)

^c STOCKHOLM HEALTH ECONOMICS   (Sweden)

^d Medical Economics Research Group MERG   (Germany)

^e Gesundheits und Pflegezentrum Russelsheim   (Germany)

Author keywords

Acute coronary syndrome; Clopidogrel; Cost effectiveness; Germany; Long term impact; Markov model

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; ECONOMIC ASPECT; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE COST; HEALTH STATUS; HEART INFARCTION; HOSPITALIZATION; HUMAN; INSURANCE; MAJOR CLINICAL STUDY; MALE; NURSING; OUTPATIENT CARE; PRIORITY JOURNAL; REHABILITATION CARE; RISK; SENSITIVITY ANALYSIS; ST SEGMENT ELEVATION; STROKE; SURVIVAL;

ACUTE CORONARY SYNDROME; ADULT; AGE FACTORS; AGED; ASPIRIN; COST-BENEFIT ANALYSIS; ELECTROCARDIOGRAPHY; FEMALE; GERMANY; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; SEX FACTORS; TICLOPIDINE;

EID: 33847143192     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-006-0006-5     Document Type: Article

References (34)

1. Statistisches Bundesamt. Datenreport 2004 - Zahlen und Fakten für die Bundesrepublik Deutschland. Schriftenreihe Band 440. Bonn 2004
2. Statistisches Bundesamt. http://www.destatis.de. (November 2004)
3. Gesundheitsberichtserstattung des Bundes 2004 [Federal Health Report]. http://www.gbe-bund.de (September 2004)
4. Klepzig, H., Krobot, K., Flettner, R., Winten, G., Zeiher, A.M.: Determinanten der Behandlungskosten der instabilen Angina pectoris. Z. Kardiol. 88, 261-269 (1999)
5. Klever-Deichert, G., Hinzpeter, B., Hunsche, E., Lauterbach, K.W.: Costs of coronary heart diseases over the remaining life time in coronary heart disease cases-an analysis of the current status of coronary heart disease cases in Germany from the social perspective. Z. Kardiol. 88(12), 991-1000 (1999)
6. Weimar, C., Weber, C., Wagner, M., Busse, O., Haberl, R.L., Lauterbach, K.W., Diener, H.C.: On behalf of the German Stroke Data Bank Collaborators. Management pattern and health care use after intracerebral hemorrhage. A cost-of-illness study from a societal perspective in Germany. Cerebrovasc. Dis. 15, 29-36 (2003)
7. Brüggenjürgen, B., Rupprecht, H.J., Willich, S.N., Spannagl, M., Ehlken, B., Smala, A., Berger, K., Diener, H.C.: Cost of atherothrombotic diseases - myocardial infarction (MI), ischaemic stroke (IS) and peripheral arterial occlusive disease (PAD) - in Germany. J. Public Health 13(4), 216-224 (2005)
8. The Clopidogrel In Unstable Angina To Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST segment elevation. N. Engl. J. Med. 345(7):494-502 (2001)
9. Lindgren, P., Jonsson, B., Yusuf, S.: Cost-effectiveness of clopidogrel in acute coronary syndrome in Sweden: a longterm model based on the CURE trial. J. Intern. Med. 255(5), 562-570 (2004)
10. Brüggenjürgen, B., Ehlken, B., Willich, S.: Kosteneffektivität von Clopidogrel bei zusätzlicher Gabe zu Acetylsalicylsäure (ASS) vs. ASS Monotherapie in Deutschland auf der Basis der CURE-Studie. Pharmacoecon. German Res. Articles 1(1), 15-24 (2003)
11. Sonnenberg, F.A., Beck, R.: Markov models in medical decision making: a practical guide. Med. Dec. Making. 13(4), 322-338 (1993)
12. Fischer, F., Schiele, R., Zahn, R., Schneider, S., Wagner, S., Senges, J.: Comparison of acute myocardial infarct in the old and new lands of unified Germany, 1996-1998. Data of the myocardial infarct register (MIR). Dtsch. Med. Wochenschr. 125(40), 1181-1185 (2000)
13. Berliner Herzinfarktregister. Ergebnisse des BHIR 1999-2001 [Myocardial Infarct Register Berlin]. http://www.herzinfarktregister.de/fakten (June 2004)
14. Heuschmann, P.U., Kolominsky-Rabas, P.L., Misselwitz, B., Hermanek, P., Leffmann, C., Von Reutern, G.M., Lachenmeyer, L., Bucker-Nott, H.J., Berger, K.: Factors influencing duration of hospitalization after stroke in Germany. Dtsch. Med. Wochenschr. 129(7), 299-304 (2004)
15. Grau, A., Weimar, C., Buggle Heinrich, A., Goertler, M., Neumaier, S., Glahn, J., Brandt, T., Hacke, W., Diener, C.: Risk factors, outcome and treatment in subtypes of ischemic stroke: the German stroke data bank. Stroke 32, 2559-2566 (2001)
16. Rote Liste: Arzneimittelverzeichnis für Deutschland. Tariff list for drugs in Germany. Editio Cantor Verlag, Aulendorf (2005)
17. Hannoveraner Konsens Gruppe: Dt. Empfehlungen zur gesundheitsö konomischen Evaluation-Revidierte Fassung des Hannoveraner Konsens. Gesundheitsökon. Qualitätsmanage. 4:A62-A65 (1999)
18. Lindgren, P., Jonsson, B., Spiesser, J., Carita, P., Gabriel, S.: Short and long term cost effectiveness analysis of clopidogrel in patients with acute coronary syndrome without ST-segment elevation (ACS) in Scandinavian countries. (Podium presentation at ISPOR 2003 in Barcelona). Value in Health. 6(6), 621 (2003)
19. Frei, A., Lindgren, P., Meiner, B.: Cost-effectiveness of clopidogrel in patients with acute coronary syndrome in Switzerland. Kardiovaskuläre Medizin. 7, 174-180 (2004)
20. Schwarz, B., Lindgren, P., Nanz, S.: Die Langzeit-Kosteneffektivität von Clopidogrel zusätzlich zu Azetylsalizylsäure bei Patienten mit akutem Koronarsyndrom ohne STStreckenhebung im österreichischen Gesundheitssystem. Pharmacoeconomics-German Research Articles 2(1), 31-41 (2004)
21. Weintraub, W.S., Mahoney, E.M., Lamy, A., Culler, S., Yuan, Y., Caro, J., Gabriel, S., Yusuf, S.: On behalf of the CURE study investigators. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. JACC. 45(6), 838-845 (2005)
22. Silber, S., Mahn, M.: Sekundärprophylaxe mit Clopidogrel bei Patienten mit klinisch manifester Atherothrombose in der täglichen hausärztlichen Praxis. Perfusion. 17, 178-184 (2004)
23. Schleinitz, M.D., Heidenreich, P.A.: A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone. Ann. Intern. Med. 142(4):251-259 (2005)
24. Eichler, H.G., Kong, S.X., Gerth, W.C., Mavros, P., Jönsson, B.: Use of cost-effectiveness analysis in health care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value in Health 7(5), 518-528 (2004)
25. Towse, A., Pritchard, C.: Does NICE have a threshold? An external view. In: Towse, A., Pritchard, C., Devlin, N. (eds.) Cost-effectiveness Thresholds. Economic and Ethical Issues. King's Fund and Office of Health Economics, London (2002)
26. Tengs, T., Adams, M., Pliskin, J., et al.: Five-hundred lifesaving interventions and their cost-effectiveness. Risk Anal. 15:369-390 (1995)
27. Garber, A.M., Phelps, C.E.: Economic foundations of cost-effectiveness analysis. J. Health Econ. 16(1), 1-31 (1997)
28. Chapman, R.H., Berger, M., Weinstein, M.C., Weeks, J.C., Goldie, S., Neumann, P.J.: When does quality-adjusting life-years matter in cost-effectiveness analysis? Health Econ. 13(5):429-436 (2004)
29. Robberstad, B.: QALYs vs. DALYs vs LYs gained: What are the differences, and what difference do they make for health care priority setting? Norsk Epidemiol. 15(2), 183-191 (2005)
30. Troche, C.J., Tacke, J., Hinzpeter, B., Danner, M., Lauterbach, K.W: Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur. Heart J. 19(Supp C), C59-C65 (1998)
31. Schädlich, P.H., Brecht, J.G., Rangoonwala, B., Huppertz, E.: Cost effectiveness of Ramipril in patients at high risk for cardiovascular events-Economic evaluation of the heart outcomes prevention evaluation (HOPE) study for Germany from the perspective of statutory health insurance. Pharmacoeconomics 22, 955-973 (2004)
32. WHO Commission on Macroeconomics and Health: Macroeconomics and Health: Investing in Health for Economic Development. Report of the Commission on Macroeconomics and Health. World Health Organization, Geneva (2001)
33. Murray, C.J., Evans, D.B., Acharya, A., Baltussen, R.M.: Development of WHO guidelines on generalised costeffectiveness analysis. Health Econ. 9(3), 235-251 (2000)
34. OECD. http://www.oecd.org (February 2005)